{"id":"W4393238683","doi":"10.1016/s0140-6736(24)00319-2","title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Medical Research Council; EMD Serono; Genentech; Pfizer; Incyte; Symphogen; Alexion Pharmaceuticals; PharmaMar; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Cancer Research UK; Regeneron Pharmaceuticals; Sarcoma UK; Daiichi-Sankyo; National Institute for Health and Care Research; Amgen; Deciphera Pharmaceuticals; National Comprehensive Cancer Network; University College London Hospitals NHS Foundation Trust; Iterion Therapeutics; Exelixis; Sanofi; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Cohort; Synovial sarcoma; Population; Sarcoma; Myxoid liposarcoma; Surgery; Clinical endpoint; Oncology; Soft tissue sarcoma; Cytopenia; Liposarcoma; Clinical trial; Pathology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001249069,0.001457964,0.00185928,0.0003348103,0.0002739224,0.001131411,0.0007400273,0.001536718,0.006724224],"category_scores_gemma":[0.0008010215,0.0004229872,0.002080179,0.0003410258,0.0007464062,0.00122353,0.000322446,0.003665861,0.00119587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007233856,"about_ca_system_score_gemma":0.0008890599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008694789,"about_ca_topic_score_gemma":0.003254491,"domain_scores_codex":[0.9996865,0.0001172047,0.00001302762,0.00005519886,0.00003188568,0.00009616383],"domain_scores_gemma":[0.9996524,0.00009265316,0.00007035417,0.00002525945,0.00002098356,0.000138367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7846208,0.01131377,0.001867557,0.002914815,0.003657425,0.0002517639,0.0002080038,0.002111172,0.01262445,0.001208446,0.01264566,0.166576],"study_design_scores_gemma":[0.8794647,0.1090662,0.002807136,0.0001288673,0.0008370325,0.0002811408,0.00006649007,0.0009781161,0.001043626,0.0005903148,0.004697051,0.00003943327],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9577714,0.02583722,0.00127991,0.0022941,0.0009440133,0.002171461,0.002599735,0.0003213372,0.006780923],"genre_scores_gemma":[0.9667277,0.0135362,0.002163742,0.00258962,0.0004311066,0.002488413,0.003480142,0.00004667069,0.008536232],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006724224,"threshold_uncertainty_score":0.02249479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1025581784956258,"score_gpt":0.4168515755341616,"score_spread":0.3142933970385358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}